GBGul Basaran

Gul Basaran

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gul Basaran has a total of 120 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Quality of life and psychosocial challenges in metastatic breast cancer: the need for tailored interventions in Turkiye

    by Gul Basaran, Nuri Karadurmus, Fatma Bugdayci Basal, Violet Aroyo, Esra Savas, Ozge Fulya Ozturk Saglam, Pınar Gunay Aslan, Mahmut Gumus

    Metastatic breast cancer (MBC) patients face numerous psychosocial difficulties, including physical symptoms, psychological distress, and fears of mortality, which heavily impact their quality of life (QoL). This study addresses the need for culturally and regionally tailored psychosocial interventions by integrating insights from semi-structured interviews with selected stakeholders in Turkiye. Utilizing a qualitative research design, interviews were conducted with a patient association representative, psycho-oncologist, and oncologists with psychological expertise. These interviews, guided by literature-driven questions, lasted about three hours each and explored the challenges MBC patients face, the existing support structures, and the dynamics of patient-doctor interactions in Turkiye. Findings reveal that MBC patients experience significant psychological distress and QoL decline due to economic issues, fears of job loss, societal stigma, family dynamics, and limited psychological support. Effective doctor-patient communication, targeted psychological interventions, and comprehensive family support are essential. Experts advocate for a holistic, psycho-oncological approach, addressing both physical and psychological needs, with recommendations for multidisciplinary care, ongoing psychiatric support, and increased awareness. This study highlights the importance of tailored, patient-centered interventions to improve the QoL of MBC patients in Turkiye.


  • Open Access

    HER2-low expression in patients with hormone receptor positive and HER2 negative advanced breast cancer treated with ribociclib or palbociclib in combination with endocrine therapy

    by Seda Kahraman, Mutlu Hızal, Özge Gümüşay, Gül Başaran, Mustafa Seyyar, Elif Sahin, Devrim Çabuk, Alper Yaşar, Vedat Bayoğlu, Ertuğrul Bayram, et al.

    Aim: Hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative breast cancer which represents the most common subgroup of metastatic breast cancer (MBC). Recently, further subclassification for HER2-negative tumors has emerged as HER2-low. There is limited knowledge regarding the effect of HER2-low expression on outcomes of patients with HR-positive and HER2-negative MBC treated with CDK 4/6 inhibitors plus hormonal therapy. Therefore, we evaluated survival parameters according to HER2-low status for this patient group in this study. Material and Methods: As the Turkish Oncology Group (TOG) Project, retrospectively collected data from 423 patients with HR-positive/HER2-negative MBC treated with ribociclib and palbociclib plus letrozole therapy was assessed. Included patients had metastatic first-line therapy and endocrine-sensitive disease. Survival outcomes were compared between HER2-negative and HER2-low patient groups. Conclusion: HER2-low status had no statistically significant impact on survival in patients treated with palbociclib or ribociclib plus letrozole.


  • Beyond traditional therapies: clinical significance of complex molecular profiling in patients with advanced solid tumours—results from a Turkish multi-centre study

    by Omer Fatih Olmez, Ahmet Bilici, Ozlem Er, Atil Bisgin, Alper Sevinc, Tulay Akman, Ruchan Uslu, Nil Molinas Mandel, Suayib Yalcin, Mehmet Teomete, et al.

    The objective of this multi-centre, real-world study was to examine the potential influence of comprehensive molecular profiling on the development of treatment decisions or adjustments for patients with advanced solid malignancies. We then evaluated the impact of these informed choices on patient treatment outcomes. The study encompassed 234 adult patients (mean age: 52.7 ± 14.3 years, 54.7% women) who were diagnosed with solid tumours at 21 different medical centres in Turkey. Remarkably, 67.9% of the patients exhibited metastasis at the time of diagnosis. We utilized an OncoDNA (Gosselies, Belgium) platform (OncoDEEP) integrating next-generation sequencing with additional tests to harvest complex molecular profiling data. The results were analyzed in relation with two specific outcomes: (i) the impact on therapeutic decisions, including formulation or modifications, and (ii) associated treatment response. Out of the 228 patients with final molecular profiling results, 118 (50.4%) had their treatment modified, whilst the remaining 110 (47.0%) did not. The response rates were comparable, with 3.9 versus 3.4% for complete response, 13.6 versus 29.3% for partial response, 66.9 versus 51.7% for progressive disease and 15.5 versus 15.5% for stable disease for treatments informed and not informed by complex molecular profiling, respectively (P = 0.16). Our real-world findings highlight the significant impact of complex molecular profiling on the treatment decisions made by oncologists for a substantial portion of patients with advanced solid tumours. Regrettably, no significant advantage was detected in terms of treatment response or disease control rates.


  • Frequency of germline pathogenic variants in breast cancer predisposition genes among young Turkish breast cancer patients

    by Aysun Dauti Isiklar, Lamiya Aliyeva, Ahmet Yesilyurt, Aykut Soyder, Gul Basaran

    Purpose One of the most important risk factors for hereditary breast and ovarian cancer is young age. We aim to report the frequency of pathogenic/likely pathogenic variants in breast cancer predisposing genes in young (≤ 40 years old) breast cancer patients who undergone 26-gene inherited cancer panel at our Breast Health Center. Methods Medical records of breast cancer patients who were referred to genetic counseling based on NCCN criteria and were ≤ 40 years of age are reviewed. The frequency of germline pathogenic/likely pathogenic variants who undergone 26-gene inherited cancer panel was analyzed. Results Among 414 breast cancer patients who were ≤ 40 years of age, 308 undergone 26-gene inherited cancer panel and 108 had next generation sequencing (NGS)-based BRCA 1 and 2 genetic testing. Median age was 35 (22–40), Family history in first degree relatives was present in 14% of patients. Forty-five percent of patients met one of the NCCN criteria for genetic testing, 41% of them met two criteria, and 14% of patients fulfilled ≥ 3 criteria. Seventy pathogenic/likely pathogenic variants (PV/LPV) were found in 65 (21%) patients. PV/LPs in BRCA genes and non-BRCA genes represented 53% and 44% of all PV/LPVs, accounting for 12% and 10% of patients in the study cohort respectively. Two PVs were present in 5 patients and eleven PVs were novel. The most common PVs were in BRCA 1 (n:18), BRCA 2 (n:19), ATM (n:7), CHEK2 (n:7) and TP53 (n:5) genes. Thirty-one percent of the patients with triple-negative tumors and 25% of the patients with hormone receptor-positive tumors had PV/LPVs with panel testing. Family history in first degree relatives (p = 0.029), the number of met NCCN criteria (p = 0.036) and axillary nodal involvement (p = 0.000) were more common in patients with PVs. When combined with patient group (n:106) who had only BRCA1 and 2 gene testing, 16% of Turkish breast cancer patients ≤ 40 years of age had PVs in BRCA genes. Conclusion One fifth of Turkish breast cancer patients ≤ 40 years of age had at least one PV/LPV in breast cancer predisposing genes with 26-gene inherited cancer panel. The frequency of PV/LPVs was higher in triple-negative young-onset patients compared to hormone receptor and Her-2 positive subtypes. Our findings regarding to frequency PV/LPVs in BRCA 1/2 and non-BRCA genes in young-onset breast cancer patients are in line with the literature.


  • Open Access

    Serologic Response to SARS-CoV-2 Vaccine in Patients with Breast Cancer

    by Aysun Işiklar, Gül Başaran, Ozde Melisa Celayi̇r, Gülçin Kahraman, Jameela Somanje, Semra Öykü Çolak, Mustafa Serteser, Nurdan Tozun

    Background: Our study aimed to measure effectiveness of Anti-S1 RBD (receptor binding domain) IgG Antibody levels against SARS (severe acute respiratory syndrome) Cov-2 in breast cancer patients and compare them with healthy participants. Methods: This prospective cross-sectional, single-center study was designed to evaluate Anti-S1 RBD IgG antibody levels following SARS-CoV-2 vaccination in 54 breast cancer patients and 56 healthy controls without cancer diagnosis. Results: Anti-S1 RBD IgG antibody test was positive in 79.6% (43/54) of breast cancer patients, in 92.9% (52/56) of participants in the control group (p=0.054) and, 63.3% in breast cancer patients who were on chemotherapy+/-molecularly targeted therapy following at least two doses of vaccinations. Hybrid vaccination (use of two different types of vaccines) and more than two doses of vaccinations were associated with higher antibody titers both in patient and control groups. Median time to vaccination was 123 days (8-427) in the entire group and was significantly associated with antibody titer. Among breast cancer patients, type and frequency of vaccination, age and use of cytotoxic therapies were significantly associated with the magnitude of antibody response to SARS-CoV-2 vaccination in our study. Conclusion: Breast cancer patients developed a lower antibody response to vaccination against COVID-19 in comparison to healthy subjects. Clinical and treatment related factors might help in tailoring future vaccination strategies for specific subsets of breast cancer patients.

  • How Do Breast Cancer Patients Present Following COVID-19 Early Peak in a Breast Cancer Center in Turkey?

    by Aysun Dauti Işıklar, Cem Deniz, Aykut Soyder, Nilgün Güldoğan, Ebru Yılmaz, Gül Başaran

    Coronavirus disease 2019 (COVID-19) has placed an unprecedented burden on healthcare systems and restricted resources for non-COVID patients worldwide. Treatment approaches and follow-up plans have been modified to prevent the risk of infection for patients and healthcare workers. Patients prefer to delay or cancel their treatments during the peak period of infection. We retrospectively reviewed the characteristics of patients with breast cancer who were consulted at our outpatient clinic right after early COVID-19 peak in May and June 2020 and compared them with the same period in 2017 to 2019. The number of patients who consulted at our outpatient medical oncology clinic declined in May and June 2020. This decline was regardless of stage and was larger in May than in June 2020. In general, the distribution of tumor subtypes [luminal, human epidermal growth factor receptor 2 (HER-2) positive, and triple negative] was not different from 2017 to 2020. Less than half of the patients received adjuvant chemotherapy following early COVID-19 peak in May and June 2020. Few patients received chemotherapy for metastatic disease, whereas many metastatic patients received endocrine therapy. None of the consulted new patients had a non-invasive disease. More patients received endocrine therapy than chemotherapy. The presentation patterns of patients with breast cancer after early COVID-19 peak differed from those during the same period in the last 3 years. The pandemic affected the number of new patients consulted and the way medical oncologists treat their patients.


  • Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer

    by Gül A. Başaran, Chris Twelves, Véronique Diéras, Javier Cortés, Ahmad Awada


  • A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378)

    by Konstantinos Tryfonidis, Gul Basaran, Jan Bogaerts, Marc Debled, Luc Dirix, Jean-Christophe Thery, Vivianne C.G. Tjan-Heijnen, Danielle Van Den Weyngaert, Tanja Cufer, Martine Piccart, et al.